Research Papers:

TIAM1 variants improve clinical outcome in neuroblastoma

Elena Sanmartín, Yania Yáñez, Victoria Fornés-Ferrer, José L. Zugaza, Adela Cañete, Victoria Castel and Jaime Font de Mora _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:45286-45297. https://doi.org/10.18632/oncotarget.16787

Metrics: PDF 1859 views  |   HTML 3078 views  |   ?  


Elena Sanmartín1, Yania Yáñez2,3, Victoria Fornés-Ferrer4, José L. Zugaza5,6,7, Adela Cañete2,3, Victoria Castel2,3 and Jaime Font de Mora1,3

1Laboratory of Cellular and Molecular Biology, Instituto de Investigación Sanitaria La Fe, Valencia, Spain

2Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, València, Spain

3Precision Oncology Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain

4Biostatistics Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain

5Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country, Leioa, Spain

6Achucarro Basque Center for Neuroscience, Bizkaia Science and Technology Park, Zamudio, Spain

7IKERBASQUE, Basque Foundation for Science, Bilbao, Spain

Correspondence to:

Jaime Font de Mora, email: [email protected]

Keywords: neuroblastoma, TIAM1, signaling networks, next generation sequencing

Received: June 04, 2016     Accepted: March 17, 2017     Published: April 03, 2017


Identification of tumor driver mutations is crucial for improving clinical outcome using a personalized approach to the treatment of cancer. Neuroblastoma is a tumor of the peripheral sympathetic nervous system for which only a few driver alterations have been described including MYCN amplification and ALK mutations. We assessed 106 primary neuroblastoma tumors by next generation sequencing using a customized amplicon-based gene panel. Our results reveal that genetic variants in TIAM1 gene associate with better clinical outcome, suggesting a role for these TIAM1 variants in preventing progression of this disease. The detected variants are located within the different domains of TIAM1 that signal to the upstream regulator RAS and downstream effector molecules MYC and RAC, which are all implicated in neuroblastoma etiology and progression. Clinical outcome was improved in tumors where a TIAM1 variant was present concomitantly with either ALK mutation or MYCN amplification. Given the function of these signaling molecules in cell survival, proliferation, differentiation and neurite outgrowth, our data suggest that the TIAM1-mediated network is essential to neuroblastoma and thus, inhibiting TIAM1 reflects a rational strategy for improving therapy efficacy in neuroblastoma.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16787